---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-001149"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:06:44.055536+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kiniksa reports ARCALYST 2023 net revenue $233.1M; abiprubart Phase 2 meets primary endpoint

## Summary
- ARCALYST 2023 net product revenue $233.1M, up ~90% YoY; Q4 2023 revenue $71.2M.
- 2024 ARCALYST net product revenue guidance set at $360M-$380M.
- Abiprubart Phase 2 RA trial met primary endpoint at 5 mg/kg weekly dose (p=0.0487); 5 mg/kg biweekly missed.
- Cash, equivalents, and short-term investments $206.3M expected to fund operations into at least 2027.
- ~9% of target 14,000 multiple-recurrence pericarditis patients on ARCALYST; salesforce expanded to ~85 reps.

## SEC filing metadata
- accession: 0001104659-24-001149
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465924001149/0001104659-24-001149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465924001149/tm241815d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-001149
- JSON: https://secwatch.observer/filing/0001104659-24-001149.json
- Plain text: https://secwatch.observer/filing/0001104659-24-001149.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported the fourth quarter and full year 2023 results: revenue ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaud. Guidance initiated.
  - Period: the fourth quarter and full year 2023
  - Revenue: ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaud
  - Guidance: initiated
  - Result: preliminary results
  source text: On January 4, 2024, Kiniksa Pharmaceuticals, Ltd. (the “Company”) issued a press release (the “Press Release”) announcing, among other things, that (i) its preliminary year-end 2023 cash, cash equivalents and short-term investments of $206.3 million (unaudited) are expected to fund its current operating plan into at least 2027 and (ii) ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaudited).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465924001149/0001104659-24-001149-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.